CD103 antibody (Azide Free)
- Known as:
- CD103 (anti-) (Azide Free)
- Catalog number:
- 10r-cd103amsp
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- CD103 antibody (Azide Free)
Related genes to: CD103 antibody (Azide Free)
- Gene:
- ITGAE NIH gene
- Name:
- integrin subunit alpha E
- Previous symbol:
- -
- Synonyms:
- CD103, HUMINAE
- Chromosome:
- 17p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1997-06-09
- Date modifiied:
- 2016-10-11
Related products to: CD103 antibody (Azide Free)
Related articles to: CD103 antibody (Azide Free)
- CD103+ tissue-resident memory T cells are emerging mediators of antitumor immunity whose prognostic significance in bladder cancer, across muscle-invasive and metastatic urothelial carcinoma, remains undefined at a meta-analytic level. We performed a systematic review and meta-analysis of cohorts with histologically confirmed muscle-invasive bladder cancer or metastatic urothelial carcinoma, comparing high vs. low CD103+ tumor-infiltrating lymphocyte density assessed by immunohistochemistry or ITGAE mRNA expression, with overall survival endpoint. PubMed, Embase, Scopus, and Cochrane CENTRAL were searched from inception through March 2026. Pooled hazard ratios (HR) with 95% confidence intervals (CIs) were estimated using a restricted maximum likelihood random-effects model. Subgroup analyses were performed by treatment context, disease stage, and assessment method. The protocol was registered at OSF (u36xv). Three studies comprising 6 cohorts were included. High CD103⁺ infiltration was significantly associated with prolonged overall survival (HR: 0.50, 95% CI: 0.30-0.83). A significant treatment-context interaction (P = 0.005) favored patients undergoing surgery with adjuvant chemotherapy (HR: 0.20) over those receiving immunotherapy (HR: 0.69). Stage-stratified analysis showed a significant interaction (P = 0.003), with pronounced benefit in muscle-invasive bladder cancer (HR: 0.27) but a non-significant trend in metastatic urothelial carcinoma (HR: 0.79). Immunohistochemistry-based cohorts showed a numerically larger effect than ITGAE mRNA cohorts. High CD103⁺ tumor-infiltrating lymphocyte infiltration may be associated with improved overall survival in bladder cancer, particularly in muscle-invasive bladder cancer patients undergoing surgery with adjuvant chemotherapy. Prospective validation in larger, stage-homogeneous cohorts is warranted to establish CD103 as a prognostic biomarker. These findings are hypothesis-generating and CD103 assessment is not currently ready for clinical use. - Source: PubMed
Publication date: 2026/08/22
Teixeira Eduardo GermanoTorres Lucas Antônio FernandesDefante Maria Luiza Rodriguesde Azevedo Fábio MedeirosSouza Vinicius Carrera - Natural killer (NK) cell-targeting immunotherapies are emerging, yet the differentiation and functional states of tumor-infiltrating NK cells remain poorly understood. Using matched single-nucleus RNA and ATAC sequencing of samples from patients with non-small cell lung cancer (NSCLC), we resolved the transcriptional and epigenetic landscape of intratumoral NK cells. We identified two tumor-associated NK (taNK) cell subsets marked by expression of (CD103) and (CD49a) that display features of tissue residency and dysfunction while preserving cytotoxic function. Trajectory and regulon analyses revealed an inflammation-driven transition from early () NK cells toward an (CD39) effector state characterized by interferon-stimulated gene (ISG) programs. Functional profiling established CD39 taNK cells as the dominant cytotoxic NK cell population with superior killing capacity that was further potentiated by NKG2A blockade. This study offers mechanistic insights into NK cell differentiation in NSCLC and establishes CD39 taNK cells as a targetable effector population for immunotherapy. - Source: PubMed
Publication date: 2026/06/05
Serger ClaraRebuffet LucasSandholzer Michael TRackwitz WiebkeFusi IreneHerzig PetraBrüggemann AnnaleaPawlow Carina AChichelnitskiy EvgenyHajnal DanielOelgarth NicoleUzun SarpSchultheiß ChristophZingg AndreasTundo SofiaLuu Thuy THojski AljazLardinois DidierNeubert LaviniaBinder MaschaMertz KirstenTrefny Marcel PKirchhammer NicoleNatoli MarinaMatter Matthias SLäubli HeinzFalk ChristineSchaeuble KarinVivier EricRomagnani AndreaZippelius Alfred - Immune cells play a pivotal role in the pathogenesis of severe pneumonia. However, the global atlas of immune cells under this condition is not fully understood. - Source: PubMed
Zhao YueanGong LinjingYu HeZhang SifanYang GuangleiWang ChaoyangWang WeiyaCai XuyuWang Ye - Invasive lobular breast carcinoma (ILC) shows specific stromal features, and a high tumor-infiltrating lymphocyte (TIL) content being associated with poor patient prognosis. Here, we reveal the underlying mechanism by performing single-cell analysis, immunohistochemistry, deconvolution of bulk RNA-sequencing in a large female ILC series and functional assays. We show that E-cadherin (CDH1)-loss in breast cancer cells prevents differentiation of FAP+ inflammatory cancer-associated fibroblasts (iCAF) into FAP+ myofibroblastic CAF, leading to iCAF accumulation in ILC. In turn, FAP+ iCAF attract TILs into the tumor center, shaping their spatial organization. Subsequently, CDH1-inactivated ILC cancer cells promote immune escape through a lack of retention and activation of ITGAE-expressing resident memory CD8 + T lymphocytes (TRM). Hence, our study uncovers reciprocal interactions between CDH1-inactivated cancer cells, FAP+ iCAF and CD8 + TRM, providing insights into the ILC stromal reaction and revealing why and how TILs are associated with poor prognosis in ILC patients, a mechanism generalizable to other CDH1-inactivated cancer types. - Source: PubMed
Publication date: 2026/05/12
Djerroudi LounesMhaidly RanaKieffer YannDamei IsabelleCroizer HugoSelvarasa VithuzaneGentric GeraldineFuhrmann LaetitiaGoncalves AndreiaCaly MartialRichardot CamilleLeclere RenaudLaas EnoraMalhaire CarolineCao KimHouthuijzen Julia MKloosterman PimJonkers JosBenoist CamilleRenault VictorBidard François-ClémentVincent-Salomon AnneMechta-Grigoriou Fatima - Human tissue-resident natural killer (NK) cells (trNK cells), broadly defined by markers of tissue residency, such as CD49a [ α ()] and CD103 [ α ()], are increasingly recognized for their immunoregulatory role in host control of infection, malignancy, and autoimmunity. Although the importance of transforming growth factor-β in trNK cell differentiation has been demonstrated, the context in which the differentiation of CD49aCD103 trNK cells occurs can result in either an immunosuppressive phenotype (e.g., decidual NK cells) or a highly cytotoxic one (e.g., some tumor trNK subsets). To understand this dichotomy better, we used a multiomic approach to molecularly characterize these cells. We identified a cytotoxic trNK (ctrNK) cell population, characterized by the expression of CD39. These ctrNK cells exhibited superior cytolytic activity against tumor target cells, enhanced capacity to infiltrate into solid tumor microenvironments, and augmented ability to control solid tumor growth in vivo compared with conventionally activated peripheral NK cells. This heightened cytolytic and infiltrative functionality of ctrNK cells appeared to be conferred, in part, by the expression of CD103 and by avidity for tumor targets. Because adoptive immune cell therapy of solid tumor malignancies has been challenged by the inefficiency of ex vivo expanded immune cells to infiltrate immunosuppressive solid tumor microenvironments, our observations that ctrNK cells can be differentiated and expanded ex vivo present a potential platform for adoptive cell therapy of solid tumor malignancies. - Source: PubMed
Publication date: 2026/05/06
Horowitz Nina BMohammad Imran AShin June HoHickey John WChockley PeterSnyder GailChen ChenLee KeeneSharma KrishnaTran QuanNejatfard AnahitaMaddineni SainiteeshDivi VasuBlish Catherine ANolan Garry PFoltz Jennifer ASunwoo John B